Abstract

Despite various therapeutic efforts, the death rate from carcinoma of the breast has not fallen significantly over the past 30 years. Recently, randomized trials testing the value of adjuvant systemic therapy in node-negative breast cancer have reported improved Disease Free Survival. Some reports have showed as much as 30 percent improvement in DFS but it has not been changed significantly in Overall Survival. Therefore, whether to give adjuvant treatment to all node negative breast cancer is discussed widely. The argument has been that such treatment is hazardous, unpleasant and expensive. Therefore, it is now recommended to the patients with node negative breast cancer only in high risk group. The tumor size, histologic grade, estrogen receptors, growth factors and onçogenes are the risk factors which are evaluated for the defining high risk group.